Aptose Biosciences Inc. announced that Dr. Bradley Thompson has been appointed to the Audit Committee, and that the NASDAQ Stock Market (NASDAQ) has notified the Company it has regained compliance with Listing Rule 5605 to maintain three independent members on the Audit Committee. On December 15, 2014, Dr. Brian Underdown, a member of the Board of Directors and Audit Committee, resigned from the Aptose Board of Directors in conjunction with the appointment of Dr. Erich Platzer to the Board. This left the Audit Committee with only two independent members until Dr. Bradley Thompson was formally appointed to the committee.